- Home
- SNDX vs PCRX Comparison
SNDX vs PCRX Comparison
Compare SNDX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- PCRX
- Stock Information
- Founded
- SNDX 2005
- PCRX 2006
- Country
- SNDX United States
- PCRX United States
- Employees
- SNDX N/A
- PCRX N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SNDX Health Care
- PCRX Health Care
- Exchange
- SNDX Nasdaq
- PCRX Nasdaq
- Market Cap
- SNDX 974.9M
- PCRX 1.1B
- IPO Year
- SNDX 2016
- PCRX 2011
- Fundamental
- Price
- SNDX $11.54
- PCRX $24.65
- Analyst Decision
- SNDX Strong Buy
- PCRX Buy
- Analyst Count
- SNDX 10
- PCRX 9
- Target Price
- SNDX $36.20
- PCRX $30.11
- AVG Volume (30 Days)
- SNDX 1.9M
- PCRX 1.2M
- Earning Date
- SNDX 05-07-2025
- PCRX 05-06-2025
- Dividend Yield
- SNDX N/A
- PCRX N/A
- EPS Growth
- SNDX N/A
- PCRX N/A
- EPS
- SNDX N/A
- PCRX N/A
- Revenue
- SNDX $23,680,000.00
- PCRX $700,966,000.00
- Revenue This Year
- SNDX $286.51
- PCRX $9.48
- Revenue Next Year
- SNDX $120.86
- PCRX $11.31
- P/E Ratio
- SNDX N/A
- PCRX N/A
- Revenue Growth
- SNDX N/A
- PCRX 3.85
- 52 Week Low
- SNDX $9.66
- PCRX $11.16
- 52 Week High
- SNDX $25.07
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- SNDX 44.37
- PCRX 51.22
- Support Level
- SNDX $9.66
- PCRX $24.10
- Resistance Level
- SNDX $11.61
- PCRX $25.35
- Average True Range (ATR)
- SNDX 1.01
- PCRX 1.49
- MACD
- SNDX 0.02
- PCRX 0.01
- Stochastic Oscillator
- SNDX 56.12
- PCRX 48.89
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.